secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2026-10-15T20:07:51+00:00
Accession:  0001193125-26-422877
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

OPKO to sell BioReference lab testing unit to LabCorp for $722M cash plus up to $150M 4Kscore earnout
--------------------------------------------------------------------------------

- LabCorp (Buyer) to pay OPKO/BioReference $722,000,000 in cash at closing, subject to upward or downward adjustment based on Business revenues at closing; no financing condition.
- Additional earnout of up to $150,000,000 in cash over up to ten years tied to LabCorp's revenue from the 4Kscore prostate cancer test.
- Assets sold include BioReference clinical/anatomic pathology testing in clinical and women's health, urology and corrections, plus the 4Kscore Test and its FDA PMA and trademark.
- Closing conditioned on HSR antitrust clearance; outside date April 14, 2027, extendable by mutual agreement. Buyer owes a $28,880,000 termination fee if required government approvals fail.
- OIG Determination was obtained as of the October 14, 2026 agreement date; Seller agreed to a no-shop covering alternative transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000119312526422877/0001193125-26-422877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000119312526422877/opk-20261014.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-422877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer